There are other biotechs with advanced cell technologies that don't have such delays. Think about the CAR T therapies that require withdrawing a patient's T cells, re-engineering those cells in a lab to express T-cell receptors, and then giving them back to the patient. Quite a process, yet 2 different companies have taken this technology from the lab into clinical trials in less than 2 years, and have already reported results at numerous medical meetings and published them in peer-reviewed journals.
News 
Market Data 
Discover 
